Therefore, geldanamycin might be an appropriate agent to recreate the beneficial effect induced by PIK3CA + HMCN1 mutations in STAD patients who can precisely target the specific vulnerability of tumors carrying LRP1B mutations; in addition, geldanamycin may be suitable for treating other cancers with LRP1B mutations. Here, HMCN1 is linked to cancer.